Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

被引：7
|
作者：
Mascarenhas, John
Higgins, Brian
Anders, Doreen
Burbury, Kate
El-Galaly, Tarec Christoffer
Gerds, Aaron T.
Gupta, Vikas
Kovic, Bruno
Maffioli, Margherita
Mesa, Ruben
Palmer, Jeanne M.
Passamonti, Francesco
Rambaldi, Alessandro
Ross, David M.
Vannucchi, Alessandro M.
Yacoub, Abdulraheem
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-135868
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study
    Passamonti, Francesco
    Burbury, Kate
    El-Galaly, Tarec Christoffer
    Gerds, Aaron T.
    Gupta, Vikas
    Higgins, Brian
    Huw, Ling-Yuh
    Maffioli, Margherita
    Mesa, Ruben
    Palmer, Jeanne M.
    Rambaldi, Alessandro
    Ross, David M.
    Vannucchi, Alessandro M.
    Yacoub, Abdulraheem
    Mascarenhas, John
    BLOOD, 2020, 136
  • [2] RESPONSE: A randomized, open-label, phase III study of ruxolitinib in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
    Verstovsek, Srdan
    Kiladjian, Jean-Jacques
    Sandor, Victor
    Lukawy, Jacek
    Li, Jingjin
    He, Shui
    Garrett, William M.
    Malek, Kamel
    Pirron, Ulrich
    Mookerjee, Bijoyesh
    Vannucchi, Alessandro M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)
    Kiladjian, Jean-Jacques
    Zachee, Pierre
    Hino, Masayuki
    Pane, Fabrizio
    Masszi, Tamas
    Harrison, Claire N.
    Mesa, Ruben A.
    Miller, Carole B.
    Passamonti, Francesco
    Durrant, Simon
    Griesshammer, Martin
    Kirito, Keita
    Besses, Carles
    Moiraghi, Beatriz
    Rumi, Elisa
    Rosti, Vittorio
    Blau, Igor W.
    Francillard, Nathalie
    Dong, Tuochuan
    Wroclawska, Monika
    Vannucchi, Alessandro M.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [4] RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
    Verstovsek, S.
    Kiladjian, J.
    Waltzman, R. J.
    Sandor, V.
    Lukawy, J.
    Garrett, W. M.
    Malek, K.
    Huber, R. M.
    Vannucchi, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial
    Verstovsek, Srdan
    Kiladjian, Jean-Jacques
    Griesshammer, Martin
    Masszi, Tamas
    Durrant, Simon T. S.
    Passamonti, Francesco
    Harrison, Claire N.
    Pane, Fabrizio
    Zachee, Pierre
    Mesa, Ruben A.
    He, Shui
    Jones, Mark
    Garrett, William M.
    Li, Jingjin
    Pirron, Ulrich
    Lawniczek, Tomasz
    Vannucchi, Alessandro M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] COMPLETE HEMATOLOGIC CONTROL WITH RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA (PV) RESISTANT TO OR INTOLERANT OF HYDROXYUREA
    Harrison, C. N.
    Masszi, T.
    Zachee, P.
    Pane, F.
    Vannucchi, A. M.
    Verstovsek, S.
    Jones, M. M.
    Hunter, D. S.
    He, S.
    Li, J.
    Khan, M.
    Habr, D.
    Kiladjian, J. -J.
    HAEMATOLOGICA, 2015, 100 : 541 - 542
  • [7] Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available
    Devos, Timothy
    Pica, Gian Matteo
    Zerazhi, Hacene
    Van Droogenbroeck, Jan
    Visanica, Sorin
    de la Fuente, Enrique Baez
    Leber, Brian
    de Almeida, Antonio Medina
    Ranta, Dana
    Martinez, Tomasa
    Kiladjian, Jean-Jacques
    Chrit, Linda
    Yin, Zhaoyu
    Foltz, Julian Perez Roncoand Lynda
    BLOOD, 2017, 130
  • [8] RUXOLITINIB PROVIDES CONSISTENT HEMATOCRIT CONTROL IN PATIENTS WITH POLYCYTHEMIA VERA (PV) RESISTANT TO OR INTOLERANT OF HYDROXYUREA
    Griesshammer, M.
    Passamonti, F.
    Durrant, S.
    Kiladjian, J. -J.
    Verstovsek, S.
    Jones, M. M.
    Hunter, D. S.
    He, S.
    Urva, S.
    Li, J.
    Khan, M.
    Habr, D.
    Vannucchi, A. M.
    HAEMATOLOGICA, 2015, 100 : 262 - 263
  • [9] Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea
    Vannucchi, Alessandro M.
    Verstovsek, Srdan
    Jones, Mark M.
    He, Shui
    Li, Jingjin
    Habr, Dany
    Kiladjian, Jean-Jacques
    BLOOD, 2014, 124 (21)
  • [10] Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study
    Theocharides, Alexandre
    Gisslinger, Heinz
    De Stefano, Valerio
    Accurso, Vincenzo
    Iurlo, Alessandra
    Devos, Timothy
    Egyed, Miklos
    Lippert, Eric
    Delgado, Regina Garcia
    Cantoni, Nathan
    Dahm, Anders E. A.
    Sotiropoulos, Damianos
    Houtsma, Erik
    Smyth, Aoife
    Iqbal, Amir
    Di Matteo, Paola
    Zuurman, Mike
    te Boekhorst, Peter A. W.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (03) : 379 - 391
12345